Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zeprumetostat + adabelimumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SHR2554 + adabelimumab is an investigational combination therapy developed by Jiangsu HengRui Medicine. It consists of zeprumetostat (SHR2554), a highly selective oral small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), and adabelimumab, a monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1). EZH2 is a histone methyltransferase that often contributes to tumor progression and immune evasion; its inhibition suppresses H3K27 trimethylation, leading to cell cycle arrest and apoptosis. Adabelimumab acts as a checkpoint inhibitor to restore anti-tumor immune responses. The combination is being evaluated in Phase II clinical trials for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), aiming to leverage potential synergy between epigenetic modulation and immune checkpoint blockade.
- Other names
- zeprumetostat + adabelimumab
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))EZH1EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on zeprumetostat + adabelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zeprumetostat + adabelimumab.